Written by
Share article:
b-rayZ has received CE mark approval for its DANAI technology, which aims to improve breast cancer detection, density assessment and quality-controlled breast positioning through its ability to adapt to the local setting and patient population it is being used on.
The company states that its DANAI offering, which integrates into the company’s b-box plus breast diagnostic suite, introduces a custom AI framework to dynamically adapt to the differing needs of breast imaging institutions and staff, enhancing diagnostic accuracy and streamlining operational efficiencies.
b-rayZ’s comprehensive mammography software portfolio is certainly enhanced by the CE mark for DANAI. However, its choice to prioritise the European market raises questions about its strategy, and its bold claims about the technology’s capabilities and impact may be challenging to realise.
